Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Phase I, Open-label, Dose-Escalation Study of SNX-5422 Plus Everolimus in Neuroendocrine Tumors (NETs) Gutierrez, M. E., Giaccone, G., Liu, S. V., Rajan, A., Guha, U., Halfdanarson, T., Kunz, P., Hinson, J. M., Orlemans, E. O. LIPPINCOTT WILLIAMS & WILKINS. 2018: 339
View details for Web of Science ID 000426086300044